Fig. 3.
Survival from 3 months into therapy by cytogenetic response at 3 months of patients in accelerated-phase CML with or without cytogenetic clonal evolution.
Survival from 3 months into therapy by cytogenetic response at 3 months of patients in accelerated-phase CML with or without cytogenetic clonal evolution.
